scholarly journals 4G/5G and A-844G Polymorphisms of Plasminogen Activator Inhibitor-1 Associated with Glioblastoma in Iran - a Case-Control Study

2015 ◽  
Vol 16 (15) ◽  
pp. 6327-6330 ◽  
Author(s):  
Honari Pooyan ◽  
Ebrahimi Ahmad ◽  
Rakhshan Azadeh
Keyword(s):  
Plasminogen Activator ◽  
Case Control Study ◽  
Plasminogen Activator Inhibitor ◽  
Case Control ◽  
Plasminogen Activator Inhibitor 1 ◽  
Activator Inhibitor ◽  
Control Study

Association of prothrombotic adipokine (plasminogen activator inhibitor-1) with TSH in metabolic syndrome: a case control study

2017 ◽  
Vol 0 (0) ◽  
Author(s):  
Ashok Kumar Ahirwar ◽  
Archana Singh ◽  
Anju Jain ◽  
Kirti Kaim ◽  
Shilpa Bhardwaj ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Thyroid Dysfunction ◽  
Case Control Study ◽  
Plasminogen Activator Inhibitor ◽  
Case Control ◽  
Plasminogen Activator Inhibitor 1 ◽  
The Mean ◽  
Activator Inhibitor ◽  
Pai 1 ◽  
Control Study

AbstractBackgroundMetabolic syndrome (MetS) involves a cluster of cardiovascular risk factors, including abnormal lipids, insulin resistance and hypertension. The aim of the present study is to investigate associations between thyroid profile and the pro-thrombotic mediator, plasminogen activator inhibitor-1 (PAI-1), in MetS and identify associated biochemical markers.Materials and methodsThe present study was a case control study and consisted of 50 diagnosed cases of MetS and 50 healthy volunteers as controls. MetS cases were further divided into two groups based on the presence and absence of subclinical hypothyroidism (SCH). Data collected included demographic profile, clinical history and routine lab investigation. Special investigations included the thyroid function test and serum PAI-1 levels.ResultsThe mean serum thyroid-stimulating hormone (TSH) levels were significantly higher in MetS cases as compared to controls (5.7 ± 1.2 mIU/L vs. 2.3 ± 1.6 mIU/L, p < 0.0001), although the mean triiodothyronine (TConclusionThe present study points towards the presence of thyroid dysfunction, in the form of subclinical hypothyroidism (SCH), in cases of MetS. In the presence of thyroid dysfunction, abnormal adipocytes may release adipokines, such as PAI-1, which lead to increased risk of thrombotic episodes in these patients. Hence, SCH should be appropriately managed.

The 4G/5G Genetic Polymorphism in the Promoter of the Plasminogen Activator Inhibitor-1 (PAI-1) Gene Is Associated with Differences in Plasma PAI-1 Activity but not with Risk of Myocardial Infarction in the ECTIM Study

1995 ◽  
Vol 74 (03) ◽  
pp. 837-841 ◽  
Author(s):  
S Ye ◽  
F R Green ◽  
P Y Scarabin ◽  
V Nicaud ◽  
L Bara ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Risk Factor ◽  
Genetic Risk ◽  
Case Control Study ◽  
Plasminogen Activator Inhibitor ◽  
Case Control ◽  
Plasminogen Activator Inhibitor 1 ◽  
Activator Inhibitor ◽  
Pai 1 ◽  
Control Study

SummaryWe have investigated the interrelationships of plasma PAI-1 activity, the PAI-1 4G/5G polymorphism and risk of myocardial infarction (MI) in the ECTIM study, a case-control study of MI based in Belfast, Lille, Strasbourg and Toulouse. Mean PAI-1 levels in cases were similar across all centres but in controls, levels in the French centres were significantly higher. Only in Belfast were PAI-1 levels higher in cases (11.7AU/ml) than controls (10.5AU/ml). The PAI-1 4G allele frequency was similar in cases and controls (0.55 and 0.54). In all groups, 4G homozygotes had the highest mean plasma PAI-1 level (4G4G vs 5G5G; cases overall: 14.2 vs 12.1 AU/ml; controls overall: 15.0 vs 12.6AU/ml), with the heterozygotes generally intermediate. The data from Belfast are consistent with the literature implicating PAI-1 level as an MI risk factor. In ECTIM, the PAI-1 4G/5G polymorphism is not a genetic risk factor for MI but is associated with PAI-1 activity. Thus homozygosity for the 4G allele may predispose to elevated PAI-1 and impaired fibrinolysis, perhaps requiring interaction with other genetic or environmental factors to influence MI risk.

scholarly journals Gender difference in plasminogen activator inhibitor-1 activity in patients with type 2 diabetes with and without albuminuria, a matched case-control study

2019 ◽  
Vol 9 (7) ◽  
pp. 484
Author(s):  
Mehrnaz Imani ◽  
Soghra Rabizadeh ◽  
Manouchehr Nakhjavani ◽  
Payam Hashemi ◽  
Shaghayegh Pezeshki ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Plasminogen Activator ◽  
Plasminogen Activator Inhibitor ◽  
Plasminogen Activator Inhibitor 1 ◽  
Matched Case ◽  
Matched Case Control Study ◽  
Activator Inhibitor ◽  
Pai 1 ◽  
Control Study

Background: Women with type 2 diabetes are more susceptible to coagulopathy disorders and endothelial dysfunction. One possible explanation is the effects of different sex hormones in inflammatory conditions. Increased plasminogen activator inhibitor-1 (PAI-1) activity has been observed as a possible predisposing factor for coagulopathy disorders and endothelial dysfunction. However, the effect of gender on PAI-1 in patients with type 2 diabetes (T2D) and albuminuria has not been studied sufficiently.Objectives: In this study, we examined whether changes of PAI-1 activity according to the albuminuria state in patients with type 2 diabetes are different in males and females.Materials and Methods: A matched case-control study was performed among participants with T2D, as 38 microalbuminuric patients were matched with 38 normoalbuminuric patients who were similar in age and body mass index (BMI). PAI-1 activity was compared between the two groups with and without gender stratification.Results: PAI-1 activity in microalbuminuric women was higher in comparison to that of the normoalbuminuric controls (P-value < 0.05). There was no significant difference in PAI-1 activity between macroalbuminuric and normoalbuminuric men. In women with type 2 diabetes and albuminuria, PAI-1 activity was independently and significantly associated with urinary albumin excretion.Conclusions: Gender differences in PAI-1 activity, seen in the early stages of diabetic nephropathy, are a possible explanation for the higher incidence of vasculopathy in women with type 2 diabetesKeywords: plasminogen activator inhibitor-1; coagulopathy; microalbuminuria; type 2 diabetes; gender

scholarly journals Perubahan Kendali Glikemik dan Plasminogen Activator Inhibitor-1 (PAI-1) pada Penyandang Diabetes Melitus Tipe-2 yang Berpuasa Ramadhan di RSUPN Cipto Mangunkusumo

2017 ◽  
Vol 1 (1) ◽  
pp. 53
Author(s):  
Khomimah Khomimah ◽  
Sarwono Waspadji ◽  
Em Yunir ◽  
Murdani Abdullah
Keyword(s):  
Plasminogen Activator ◽  
Plasminogen Activator Inhibitor ◽  
Self Control ◽  
Plasminogen Activator Inhibitor 1 ◽  
Group Design ◽  
Plasma Angiotensin ◽  
Activator Inhibitor ◽  
Pai 1 ◽  
Control Study ◽  
Diabetes Melitus

Pendahuluan. Penyandang diabetes melitus (DM) mempunyai risiko tinggi mengalami penyakit kardiovaskular (PKV), yang progresivitasnya dipercepat oleh penurunan kapasitas fibrinolisis. Penyandang DM yang berpuasa Ramadhan mengalami berbagai perubahan yang dapat memengaruhi kendali glikemik dan status fibrinolisisnya. Penelitian ini bertujuan mengetahui penurunan fruktosamin dan plasminogen activator inhibitor-1 (PAI-1).Metode. Penelitian dikerjakan dengan metode kuasi eksperimental one group design self control study pada penyandang DM tipe-2 yang berpuasa Ramadhan dan berusia 40-60 tahun. Hasil. Penelitian ini menunjukkan sebagian besar subjek memiliki 3 faktor risiko PKV dan dengan kendali glikemik yang jelek sebelum puasa Ramadhan. Terdapat penurunan yang bermakna pada glukosa puasa plasma, tetapi tidak bermakna pada glukosa darah 2 jam setelah makan. Tidak terdapat perbedaan asupan kalori pada 18 subjek yang dianalisis. Tidak didapatkan penurunan yang bermakna pada fruktosamin serum maupun PAI-1 plasma. Kendali glikemik yang dicapai sebelum dan asupan kalori selama berpuasa Ramadhan kemungkinan merupakan faktor yang memengaruhi penurunan fruktosamin. Selain glukosa darah, faktor yang memengaruhi kadar PAI-1 plasma di antaranya adalah insulin plasma, angiotensin II, faktor pertumbuhan dan inflamasi, yang tidak diukur dalam penelitian ini.Simpulan. Tidak terdapat penurunan kadar fruktosamin serum sesudah berpuasa Ramadhan lebih dari sama dengan 21 hari pada penyandang DM tipe-2. Tidak terdapat penurunan kadar plasminogen activator inhibitor-1 (PAI-1) plasma sesudah berpuasa Ramadhan lebih dari sama dengan 21 hari pada penyandang DM tipe-2. 

Sign in / Sign up

Export Citation Format

Share Document